Savara Inc (SVRA)

$5.52 +0.15 (2.79%)
Market Cap 1.10B
Revenue (ttm) 0.00
Net Income (ttm) -118.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.21
Volume 506,900
Avg Vol 1,832,846
Day's Range N/A - N/A
Shares Out 205.46M
Stochastic %K 27%
Beta 0.29
Analysts Strong Sell
Price Target $10.94

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Address:
The Tannery, Suite 200 19 W. College Avenue West College Avenue, Yardley, United States
TraderXLII
TraderXLII Aug. 19 at 3:44 PM
Could $SVRA go north after FDA decision on MOLBREEVI after Aug 22, 2026? Is a catalyst driven short squeeze possible? North or nuts?
0 · Reply
NFA_DYOR
NFA_DYOR Aug. 18 at 10:12 PM
$SVRA FDA catalyst pushed to Nov For now will swing trade
0 · Reply
keitrader
keitrader Aug. 18 at 12:44 PM
$SVRA ✨️ started small position yesterday ✨️
0 · Reply
Frank_Linde
Frank_Linde Aug. 14 at 8:06 PM
$SVRA I might have to buy a big chunk on monday. This looks almost too good
1 · Reply
art62
art62 Aug. 14 at 11:49 AM
$SVRA Jefferies TSai: "Q2 EPS: Likely Approval in Nov 2026 for Lung Disease, Robust Launch Thereafter We remain 90%+ confident in Molbreevi's (inhaled GM-CSF) US approval in aPAP rare lung disease by Nov 22, 2026 PDUFA ($500M+ oppty), supporting a Q1:27 launch. Mgmt's patient-finding efforts offer line-of-sight to well over 1000+ patients, indicating an initial launch bolus. A hypothetical $400K net price (our est) suggests 2027 cons of $70M+ is achievable. Net-net, $500M US sales x 4-5x multiple (biosimilars are unlikely) = $2.0-2.5B valuation (vs $1.3B+ cap)."
2 · Reply
Frank_Linde
Frank_Linde Aug. 14 at 11:16 AM
$SVRA 🎯 Closest to Your Ideal Setup Your checklist: •✅ Short interest >20% •✅ RSI 55-75 •✅ Positive momentum •✅ High days-to-cover •⚠️ Relative volume >3× average •⚠️ Confirmed breakout Best Match: SVRA •Short interest: 23.3% ✅ •Days-to-cover: 20.8 ✅ •RSI: 56 ✅ •Momentum: +7.8% ✅ •Readiness: "Igniting" ✅
0 · Reply
Richterscale
Richterscale Aug. 13 at 5:39 PM
$SVRA why the sell off?
0 · Reply
Rocket22fb
Rocket22fb Aug. 13 at 1:52 PM
$SVRA starting a position here. GLTA
0 · Reply
Richterscale
Richterscale Aug. 12 at 11:50 PM
$SVRA When moon?
0 · Reply
Merlintrader
Merlintrader Aug. 12 at 4:21 PM
Savara Stock Hub 2026: the November 22 PDUFA for MOLBREEVI, the IMPALA-2 data read precisely, and a balance sheet built for one decision. Free to read, no subscription. $SVRA https://www.merlintrader.com/savara-svra-stock-hub-2026/
0 · Reply
Latest News on SVRA
Savara reports Q2 EPS (16c), consensus (15c)

2026-08-11T20:15:36.000Z - 7 days ago

Savara reports Q2 EPS (16c), consensus (15c)

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 11, 2026, 4:05 PM EDT - 7 days ago

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Savara Quarterly report: Q2 2026

Savara Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Savara Earnings release: Q2 2026

Savara Slides: Corporate presentation

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Savara Slides: Corporate presentation

Savara announces EPO granted a patent covering formulation of Molbreevi

2026-07-30T12:38:55.000Z - 20 days ago

Savara announces EPO granted a patent covering formulation of Molbreevi

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Jul 30, 2026, 8:05 AM EDT - 20 days ago

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Savara Slides: Corporate presentation

Jul 14, 2026, 8:00 AM EDT - 5 weeks ago

Savara Slides: Corporate presentation

Palvella Therapeutics appoints Savara CEO Matt Pauls to board

2026-06-30T11:45:19.000Z - 7 weeks ago

Palvella Therapeutics appoints Savara CEO Matt Pauls to board

PVLA

Savara Announces New Employment Inducement Grant

Jun 12, 2026, 4:05 PM EDT - 2 months ago

Savara Announces New Employment Inducement Grant

Savara says CFO Dave Lowrance stepping down for health reasons

2026-06-08T20:12:31.000Z - 2 months ago

Savara says CFO Dave Lowrance stepping down for health reasons

Savara Announces Chief Financial and Administrative Officer Transition

Jun 8, 2026, 4:05 PM EDT - 2 months ago

Savara Announces Chief Financial and Administrative Officer Transition

Savara Transcript: AGM 2026

Jun 4, 2026, 3:00 PM EDT - 2 months ago

Savara Transcript: AGM 2026

Savara Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:05 AM EDT - 2 months ago

Savara Transcript: Jefferies Global Healthcare Conference 2026

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 27, 2026, 4:05 PM EDT - 2 months ago

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara presents poster at ATS 2026 International Conference on IMPALA-2

2026-05-20T12:22:28.000Z - 3 months ago

Savara presents poster at ATS 2026 International Conference on IMPALA-2

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

May 20, 2026, 8:15 AM EDT - 3 months ago

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

ATS

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 19, 2026, 2:15 PM EDT - 3 months ago

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 10:00 AM EDT - 3 months ago

Savara Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 18, 2026, 2:55 PM EDT - 3 months ago

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara reports Q1 EPS (15c), consensus (14c)

2026-05-12T21:14:03.000Z - 3 months ago

Savara reports Q1 EPS (15c), consensus (14c)

Savara Reports First Quarter Financial Results and Provides Business Update

May 12, 2026, 4:05 PM EDT - 3 months ago

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Slides: Corporate presentation

May 12, 2026, 4:00 PM EDT - 3 months ago

Savara Slides: Corporate presentation

Savara Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Savara Quarterly report: Q1 2026

Savara Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Savara Earnings release: Q1 2026

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

May 11, 2026, 4:05 PM EDT - 3 months ago

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Savara Proxy statement: Proxy filing

Savara Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Savara Proxy statement: Proxy filing

Savara assumed with an Outperform at Oppenheimer

2026-04-24T11:40:14.000Z - 4 months ago

Savara assumed with an Outperform at Oppenheimer

Savara says FDA extended review for Molgramostim BLA

2026-04-15T20:10:15.000Z - 4 months ago

Savara says FDA extended review for Molgramostim BLA

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 15, 2026, 4:05 PM EDT - 4 months ago

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Apr 14, 2026, 8:05 AM EDT - 4 months ago

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Savara Proxy statement: Proxy filing

Savara announces MHRA accepted submission of Molbreevi MAA

2026-04-07T12:11:43.000Z - 4 months ago

Savara announces MHRA accepted submission of Molbreevi MAA

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 7, 2026, 8:05 AM EDT - 4 months ago

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Slides: Corporate presentation

Apr 7, 2026, 7:00 AM EDT - 4 months ago

Savara Slides: Corporate presentation

Savara Slides: Corporate presentation

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Savara Slides: Corporate presentation

Savara announces EMA validation of MAA for MOLBREEVI

2026-03-30T12:19:50.000Z - 5 months ago

Savara announces EMA validation of MAA for MOLBREEVI

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 30, 2026, 8:05 AM EDT - 5 months ago

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara reports Q4 EPS (13c), consensus (12c)

2026-03-13T12:50:39.000Z - 5 months ago

Savara reports Q4 EPS (13c), consensus (12c)

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 13, 2026, 8:05 AM EDT - 5 months ago

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Savara Earnings release: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 5 months ago

Savara Earnings release: Q4 2025

Savara Annual report: Q4 2025

Mar 13, 2026, 7:00 AM EDT - 5 months ago

Savara Annual report: Q4 2025

Savara Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 5 months ago

Savara Slides: Corporate presentation

Savara Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 5 months ago

Savara Transcript: The Citizens Life Sciences Conference 2026

Savara announces receipt of Day 74 Letter from FDA

2026-03-06T21:15:14.000Z - 5 months ago

Savara announces receipt of Day 74 Letter from FDA

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 6, 2026, 4:05 PM EST - 5 months ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 5 months ago

Savara Slides: Corporate presentation

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Mar 4, 2026, 4:05 PM EST - 5 months ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 9:20 AM EST - 6 months ago

Savara Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Savara says FDA files BLA for Molbreevi

2026-02-20T21:25:34.000Z - 6 months ago

Savara says FDA files BLA for Molbreevi

Savara announces BLA for Molbreevi filed for review by FDA

2026-02-20T21:20:31.000Z - 6 months ago

Savara announces BLA for Molbreevi filed for review by FDA

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Feb 20, 2026, 4:15 PM EST - 6 months ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 12:30 PM EST - 6 months ago

Savara Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Feb 4, 2026, 4:05 PM EST - 6 months ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Jan 27, 2026, 8:05 AM EST - 7 months ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Savara Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 7 months ago

Savara Transcript: 44th Annual J.P. Morgan Healthcare Conference

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 4:05 PM EST - 7 months ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Slides: Corporate presentation

Jan 8, 2026, 7:00 AM EST - 7 months ago

Savara Slides: Corporate presentation

Savara price target raised to $10 from $8 at H.C. Wainwright

2025-12-23T11:11:14.000Z - 8 months ago

Savara price target raised to $10 from $8 at H.C. Wainwright

Savara resubmits Molbreevi BLA to the FDA

2025-12-22T13:42:07.000Z - 8 months ago

Savara resubmits Molbreevi BLA to the FDA

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 22, 2025, 8:30 AM EST - 8 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:05 AM EST - 8 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara announces EPO intention to grant Molbreevi patent application

2025-12-11T13:16:21.000Z - 8 months ago

Savara announces EPO intention to grant Molbreevi patent application

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 11, 2025, 8:05 AM EST - 8 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:00 AM EST - 9 months ago

Savara Transcript: Evercore ISI 8th Annual HealthCONx Conference

Savara Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 2:30 PM EST - 9 months ago

Savara Transcript: Piper Sandler 37th Annual Healthcare Conference

Savara rumor highlighted in Betaville blog

2025-12-02T19:25:21.000Z - 9 months ago

Savara rumor highlighted in Betaville blog

Savara issues patent for Molbreevi from European Patent Office

2025-12-02T13:36:08.000Z - 9 months ago

Savara issues patent for Molbreevi from European Patent Office

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 9 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 7:00 AM EST - 9 months ago

Savara Transcript: Jefferies London Healthcare Conference 2025

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 9 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Savara Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

Savara Earnings release: Q3 2025

Savara Quarterly report: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

Savara Quarterly report: Q3 2025

Savara Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 10 months ago

Savara Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 10 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 10 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 10 months ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 10 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 10 months ago

Savara Announces Chief Medical Officer (CMO) Transition

TraderXLII
TraderXLII Aug. 19 at 3:44 PM
Could $SVRA go north after FDA decision on MOLBREEVI after Aug 22, 2026? Is a catalyst driven short squeeze possible? North or nuts?
0 · Reply
NFA_DYOR
NFA_DYOR Aug. 18 at 10:12 PM
$SVRA FDA catalyst pushed to Nov For now will swing trade
0 · Reply
keitrader
keitrader Aug. 18 at 12:44 PM
$SVRA ✨️ started small position yesterday ✨️
0 · Reply
Frank_Linde
Frank_Linde Aug. 14 at 8:06 PM
$SVRA I might have to buy a big chunk on monday. This looks almost too good
1 · Reply
art62
art62 Aug. 14 at 11:49 AM
$SVRA Jefferies TSai: "Q2 EPS: Likely Approval in Nov 2026 for Lung Disease, Robust Launch Thereafter We remain 90%+ confident in Molbreevi's (inhaled GM-CSF) US approval in aPAP rare lung disease by Nov 22, 2026 PDUFA ($500M+ oppty), supporting a Q1:27 launch. Mgmt's patient-finding efforts offer line-of-sight to well over 1000+ patients, indicating an initial launch bolus. A hypothetical $400K net price (our est) suggests 2027 cons of $70M+ is achievable. Net-net, $500M US sales x 4-5x multiple (biosimilars are unlikely) = $2.0-2.5B valuation (vs $1.3B+ cap)."
2 · Reply
Frank_Linde
Frank_Linde Aug. 14 at 11:16 AM
$SVRA 🎯 Closest to Your Ideal Setup Your checklist: •✅ Short interest >20% •✅ RSI 55-75 •✅ Positive momentum •✅ High days-to-cover •⚠️ Relative volume >3× average •⚠️ Confirmed breakout Best Match: SVRA •Short interest: 23.3% ✅ •Days-to-cover: 20.8 ✅ •RSI: 56 ✅ •Momentum: +7.8% ✅ •Readiness: "Igniting" ✅
0 · Reply
Richterscale
Richterscale Aug. 13 at 5:39 PM
$SVRA why the sell off?
0 · Reply
Rocket22fb
Rocket22fb Aug. 13 at 1:52 PM
$SVRA starting a position here. GLTA
0 · Reply
Richterscale
Richterscale Aug. 12 at 11:50 PM
$SVRA When moon?
0 · Reply
Merlintrader
Merlintrader Aug. 12 at 4:21 PM
Savara Stock Hub 2026: the November 22 PDUFA for MOLBREEVI, the IMPALA-2 data read precisely, and a balance sheet built for one decision. Free to read, no subscription. $SVRA https://www.merlintrader.com/savara-svra-stock-hub-2026/
0 · Reply
ckruel
ckruel Aug. 12 at 2:56 PM
$SVRA https://tipranks.onelink.me/WJho/zp2l07fb Buy rating reiterated
0 · Reply
svedding
svedding Aug. 9 at 2:03 PM
$SVRA https://www.businesswire.com/news/home/20260730546415/en/Savara-Announces-European-and-Australian-Patent-Offices-Have-Granted-Patents-for-the-Liquid-Formulation-of-MOLBREEVI-Providing-Protection-in-Europe-and-Australia-Until-March-2041
0 · Reply
Richterscale
Richterscale Aug. 8 at 1:31 AM
$SVRA Anyone left on the forum? Anyone think if this gets a buyout it’s mid $20’s?
1 · Reply
svedding
svedding Aug. 6 at 11:26 AM
$SVRA https://seekingalpha.com/article/4930599-savara-high-potential-binary-bet-cruising-to-pdufa-after-3-month-speed-bump
0 · Reply
Richterscale
Richterscale Aug. 5 at 12:03 AM
$SVRA what’s going on?
0 · Reply
JustBen47
JustBen47 Aug. 2 at 10:52 AM
$SVRA Bullish for a bounce!!
0 · Reply
Richterscale
Richterscale Jul. 31 at 5:00 PM
$SVRA https://www.businesswire.com/news/home/20260730546415/en/
0 · Reply
Richterscale
Richterscale Jul. 28 at 8:33 PM
$SVRA Kris the board is dead but agreed on strategy. I’ve owned this since $.90. Hopefully a buyout in the mid $20’s
0 · Reply
TheMyth2020
TheMyth2020 Jul. 28 at 5:37 PM
$SVRA looks like its a good time to start a position for the november pdfua day run up.
0 · Reply
jjangles123
jjangles123 Jul. 25 at 10:52 PM
$SVRA Thinking of entering Monday. What are everyones thoughts? Seems like loads of cash runway well past PDUFA
0 · Reply
Richterscale
Richterscale Jul. 24 at 6:02 PM
$SVRA The cone of silence
0 · Reply
Richterscale
Richterscale Jul. 17 at 9:45 PM
$SVRA Back to the AH shannigans
0 · Reply